Medication
Ended Awarded Last action
- Contract number
- 36C24121N0088
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 1
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $113,304
Award facts
- Contract value 100% obligated
- $113,303.91 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15275, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$10,375 | |
| Other Administrative Action | $2,479 | |
| Supplemental Agreement for work within scope | -$27 | |
| Original award | $121,226 |
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 1, awarded a Blanket Purchase Agreement (BPA) call contract to Otsuka America Pharmaceutical Inc. on October 15, 2020, with a ceiling value of $113,303.91 and a completion date of October 14, 2021. This firm fixed-price contract, which does not utilize a set-aside designation, falls under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract is for medication delivery to VA facilities in Pittsburgh, Pennsylvania, and represents a delivery order against Otsuka's larger GSA schedule contract. Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer headquartered in Rockville, Maryland, is a primary supplier of specialty pharmaceuticals to the VA, with particular expertise in complex medical conditions.
This BPA call is part of Otsuka's broader relationship with the Veterans Health Administration, which includes a master Blanket Purchase Agreement valued at approximately $83.3 million for Jynarque (tolvaptan), a specialized medication used to treat autosomal dominant polycystic kidney disease and hyponatremia. The company's federal supply schedule contract demonstrates its established capability to supply critical pharmaceutical treatments to veteran populations across multiple VA Integrated Service Networks. The delivery order structure enables VA healthcare facilities to efficiently procure medications through streamlined procurement processes, supporting the agency's mission of providing comprehensive specialized pharmaceutical care to veterans nationwide.
Quick answers
Who was awarded contract 36C24121N0088?
36C24121N0088 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 1 (Veterans Health Administration) on October 15, 2020.
How much is contract 36C24121N0088 worth?
The government has obligated $113,304 on 36C24121N0088.
Is contract 36C24121N0088 an order under another contract?
Yes. 36C24121N0088 is a BPA call under 36F79720D0099-36E79720A0007, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24121N0088 competed?
The extent of competition for 36C24121N0088 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award